Advertisement

Glaucoma Medications’ Effect on Ocular Surface

  • Giedre Pakuliene
Chapter

Abstract

Finding a perfect topical drug for glaucoma patients can be a challenging task. A perfect drug must not only be sufficiently effective, but also tolerated well by the patient. Evaluating antiglaucomatous drugs’ effects to ocular surface, three major factors must be considered: ocular surface toxicity, inflammation and allergy.

References

  1. 1.
    Lee SY, Lee H, Bae HW, Kim T-i, Kim CY. Tear lipid layer thickness change and topical anti-glaucoma medication use. Optom Vis Sci. 2016;93(10):1210–7.  https://doi.org/10.1097/OPX.0000000000000943.CrossRefPubMedGoogle Scholar
  2. 2.
    Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2010;26(3):287–92.  https://doi.org/10.1089/jop.2009.0134.CrossRefPubMedGoogle Scholar
  3. 3.
    Lin L, Zhao YJ, Chew PTK, Sng CCA, Wong H-T, Yip LW, Tuck Seng W, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014;48(12):1585–93.  https://doi.org/10.1177/1060028014548569.CrossRefPubMedGoogle Scholar
  4. 4.
    Mishra D, Sinha BP, Kumar MS. Comparing the efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the treatment of primary open angle glaucoma. Korean J Ophthalmol. 2014;28(5):399–407.  https://doi.org/10.3341/kjo.2014.28.5.399.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Figus M, Nardi M, Piaggi P, Sartini M, Guidi G, Martini L, Lazzeri S. Bimatoprost 0.01% vs Bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. Eye (Basingstoke). 2014;28(4):422–9.  https://doi.org/10.1038/eye.2013.304.CrossRefGoogle Scholar
  6. 6.
    Chen J, Dinh T, Woodward DF, Holland M, Yuan Y-D, Lin T-H, Wheeler L a. Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. Cardiovasc Drug Rev. 2005;23(3):231–46.CrossRefGoogle Scholar
  7. 7.
    Schrems WA, Schrems-Hoesl LM, Mardin CY, Horn FK, Juenemann AGM, Kruse FE, Braun JM, Laemmer R. The effect of long-term Antiglaucomatous drug administration on central corneal thickness. J Glaucoma. 2016;25(3):274–80.  https://doi.org/10.1097/IJG.0000000000000190.CrossRefPubMedGoogle Scholar
  8. 8.
    Asbell PA, Potapova N. Effects of topical Antiglaucoma medications on the ocular surface. Ocul Surf. 2005;3(1):27–40.  https://doi.org/10.1016/S1542-0124(12)70120-9.CrossRefPubMedGoogle Scholar
  9. 9.
    Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011;28(4):267–82.  https://doi.org/10.2165/11588830-000000000-00000.CrossRefPubMedGoogle Scholar
  10. 10.
    Trocme S, Hwang LJ, Bean GW, Sultan MB. The role of Benzalkonium chloride in the occurrence of punctate keratitis: a meta-analysis of randomized, controlled clinical trials. Ann Pharmacother. 2010;44(12):1914–21.  https://doi.org/10.1345/aph.1P268.CrossRefPubMedGoogle Scholar
  11. 11.
    Weissman SS, Asbell PA. Effects of topical Timolol (0.5%) and Betaxolol (0.5%) on corneal sensitivity. Br J Ophthalmol. 1990;74(7):409–12. http://www.ncbi.nlm.nih.gov/pubmed/2378856 CrossRefGoogle Scholar
  12. 12.
    Zhao JC, Chen T. Brinzolamide induced reversible corneal Decompensation. Br J Ophthalmol. 2005;89(3):389–90.  https://doi.org/10.1136/bjo.2004.049544.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mantelli F, Abdolrahimzadeh S, Mannino G, Lambiase A. Unusual case of angle closure Glaucoma in a patient with Neurofibromatosis type 1. Case Rep Ophthalmol. 2014;5(3):386–91.  https://doi.org/10.1159/000369334.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Osborne SA, Montgomery DMI, Morris D, McKay IC. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye. 2005;19(2):129–37.  https://doi.org/10.1038/sj.eye.6701441.CrossRefPubMedGoogle Scholar
  15. 15.
    Manni G, Centofanti M, Sacchetti M, Oddone F, Bonini S, Parravano M, Bucci MG. Demographic and clinical factors associated with development of Brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma. 2004;13(2):163–7. http://www.ncbi.nlm.nih.gov/pubmed/15097264 CrossRefGoogle Scholar
  16. 16.
    Carrasco MA, Schlaen BA, Zárate JO. Brimonidine–timolol fixed combination induced granulomatous inflammation of the eye. Int Ophthalmol. 2013;33(5):557–60.  https://doi.org/10.1007/s10792-012-9688-0.CrossRefPubMedGoogle Scholar
  17. 17.
    Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical Brimonidine. Am J Ophthalmol. 2000;130(3):287–91. http://www.ncbi.nlm.nih.gov/pubmed/11020406 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Giedre Pakuliene
    • 1
  1. 1.Lithuanian University of Health ScienceKaunasLithuania

Personalised recommendations